Bionomics Ltd.

OTCQB: BNOEF

Company Logo

Company Overview

Bionomics (ASX: BNO) (OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of clinical-stage ion channel programs targeting pain, depression, cognition and epilepsy.

Financial Highlights

$2,194,059

Revenue (ttm)

-$2,635,298

Gross Profit (ttm)

$0.00

Diluted EPS (ttm)

Management Team

Dr. Errol B. De Souza
Exec. Chairman

Mr. Adrian Hinton
Acting Chief Financial Officer

Prof. Paul Rolan
Consultant Chief Medical Officer of Clinical Neuroscience

Ms. Suzanne Irwin B.Com., FCIS
Company Sec.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
0 (0%)

Insider Ownership
4%